

Blood Transfusion GC1 minutes

Blood Transfusion (tranexamic acid update) – committee meeting 1 minutes

Date: 09/09/2025

Location: Virtual

Minutes: Final

Committee members present:

Ian Bernstein	Committee Chair	Present for items 1-11
Martin Besser	Haematologist	Present for items 1-11
Margaret Cheng	Lay member	Present for items 1-11
Claire Frank	Pharmacist	Present for items 1-11
Mario Ganau	Surgeon (neurosurgeon)	Present for items 1-11
Nadia Ladak	Anaesthetist (paediatrics)	Present for items 1-11
Sarah Markham	Lay member	Present for items 1-11
Sandip Nandhra	Surgeon (vascular)	Present for items 1-11
Kelly Nwankiti	Nurse (blood products)	Present for items 1-11
Antony Palmer	Surgeon (orthopaedic)	Present for items 1-11
Felicity Plaat	Anaesthetist (adults)	Present for items 1-11
Akshay Shah	Anaesthetist (adults)	Present for items 1-11
Louise Strickland	Nurse (perioperative)	Present for items 1-11
Marisa Taylor-Clarke	Surgeon (obstetrics)	Present for items 1-11
Laura Warner	Surgeon (ENT)	Present for items 1-11

In attendance NICE:

Alexandra Bonnon	Health Economist	Present for items 1-11
Danielle Conroy	Project Manager	Present for items 1-11
Cheryl Hookway	Implementation Support Manager (observing)	Present for items 1-11
Sophia Kemmis-Betty	Health Economics Advisor	Present for items 1-11
Jenny Kendrick	Information Specialist	Present for items 1-8
Clifford Middleton	Topic Lead	Present for items 1-11
Joanna Perkin	Senior Guidance Content Designer	Present for items 1-11
Rachel Walsh	Technical Analyst	Present for items 1-8
George Wood	Senior Technical Analyst	Present for items 1-11

Apologies:

Mark Hills	Operating Department Practitioner, committee
Magdalena Watras	Pharmacist Clinical Adviser, NICE

1. Welcome, Introductions and apologies

The Chair, Ian Bernstein (IB) welcomed the committee members and NICE attendees to the first in-development committee meeting for the NICE Blood Transfusion tranexamic acid update.

The group introduced themselves and apologies were noted.

2. Declaration of interests

The Chair introduced Clifford Middleton (CM), Topic Lead who provided an overview and background to NICE's policy on declaring and managing interests for NICE advisory committees. CM explained what interests needed to be declared and when and when a declared interest could represent a conflict of interest and the action that should be taken.

The committee were asked to declare any new, unrecorded, interests to the group that were relevant to the matter under consideration today.

No new interests were declared.

The Chair thanked CM for his input.

3. Clinical evidence:

- Presentation for effectiveness of tranexamic acid**

The Chair introduced George Wood (GW), Senior Technical Analyst who presented the clinical evidence for the effectiveness of tranexamic acid for people with minor anticipated blood loss.

This included details of the analysis undertaken, the findings and identified gaps in the evidence.

The committee had the opportunity to ask questions and offer their expert opinion.

4. Committee discussion

The committee discussed what was presented as a group and answered questions from the NICE team.

The Chair thanked the committee for their input.

5. Introduction to health economics

The Chair introduced Alexandra Bonnon (AB), Health Economist who introduced the topic of health economics for committee's understanding. This included what cost-effectiveness is and how it is used in NICE guidelines, cost evaluation, how health outcomes are measured and how to decide if an intervention is cost effective compared to standard care.

The committee had the opportunity to discuss what was presented and ask questions.

6. Economics evidence:

- **Presentation for cost-effectiveness of tranexamic acid**

AB then proceeded to present the cost-effectiveness evidence for the use of tranexamic acid in low-risk bleed surgeries.

The committee had the opportunity to discuss what was presented and ask questions. This included the study results, population and any limitations which may impact the findings.

The Chair thanked AB for her contribution to the meeting.

7. Clinical evidence:

- **Presentation for safety of tranexamic acid**

GW presented the evidence for the safety of tranexamic acid for committee's consideration.

The committee considered the study findings and their limitations, gaps in the evidence and identified outcomes.

The committee had the opportunity to discuss what was presented and ask questions.

8. Clinical evidence:

- **Presentation for safety of tranexamic acid (continued)**

The presentation continued after a short break.

The Chair thanked GW for their contribution to the meeting.

9. NHS England tranexamic acid proposal

CM provided the committee with an update on a proposal by NHS England on the use of tranexamic acid which is relevant to the work of the committee.

The committee offered their opinion which CM will take away for consideration and feed back at the next meeting once the NICE team and Committee Chair have had the opportunity to meet with NHS England to discuss the matter further.

10. Committee discussion

Blood Transfusion GC1 minutes

The committee started to collectively discuss the evidence, but further consideration and recommendation drafting was deferred to the next meeting.

The Chair thanked the committee for their input.

11. Next steps and AOB

IB summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, IB brought the meeting to a close.

Date of next meeting: 30 September 2025

Location of next meeting: Virtual